stonks4u
Sign up free
KPTI logo

KPTI Karyopharm Therapeutics Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$2.02
+0.03 (+1.51%)

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Ex…

Market Cap: $45.78Mwww.karyopharm.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

153
5084119153
Aug 10Aug 13

Quote

Day Range
$1.97 – $2.06
52-Week Range
$1.80 – $10.99
Volume
$875.0K
Market Cap
$45.78M
50-Day Avg
$7.46
200-Day Avg
$7.42
Prev Close
$1.99
Open
$2.00

Valuation & Ratios

P/E Ratio
-0.41
EPS
$-17.93
P/B Ratio
-0.27
P/S Ratio
0.55
Debt/Equity
-0.80
Current Ratio
1.12
Dividend Yield
+0.0%
Gross Margin
+95.9%

Returns & Efficiency

Return on Equity
+66.9%
Return on Assets
-180.8%
FCF Yield
-93.6%
EV/EBITDA
-1.69

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$146.07M$-196.04M$-17.93
2024$145.24M$-76.42M$-9.41
2023$146.03M$-143.10M$-18.79
2022$157.07M$-165.29M$-30.28
2021$209.82M$-124.09M$-24.75

Social Signal Score

53
5d
53
3 mentions
—
30d
53
4 mentions
—
60d
53
4 mentions
—
90d
53
4 mentions
—
news: 4

Earnings

Mon, Nov 2(in 3 months)

Consensus estimate $-1.33 per share

4of 7 quarters beat consensus

Typical surprise +1.3% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 13$-2.32 vs $-1.37miss
  • Thu, May 14$-1.24 vs $-1.45beat
  • Thu, Feb 12$-2.23 vs $-2.26beat
  • Mon, Nov 3$-3.82 vs $-3.47miss
  • Mon, Aug 11$-4.32 vs $-3.80miss
  • Mon, May 12$-2.77 vs $-4.21beat

Estimates and results for KPTI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

KPTIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (4)

  • Newszacks.com·2d ago·Neutral

    Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.32 per share versus the Zacks Consensus Estimate of a loss of $1.53. This compares to a loss of $4.32 per share a year ago.

    View source ↗
  • Newsprnewswire.com·2d ago·Neutral

    Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission – Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Remains on Track – – Planned sNDA for Selinexor plus Ruxolitinib Supported by Phase 3 SENTRY Results Presented at ASCO and EHA and Published in the Journal of Clinical Oncology; Potential to Become the First Approved Combination Therapy

    View source ↗
  • Newsglobenewswire.com·3d ago·Neutral

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Karyopharm Therapeutics Inc. (“Karyopharm” or the “Company”) (NASDAQ: KPTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

    View source ↗
  • Newsprnewswire.com·5d ago·Neutral

    Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 -- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET -- NEWTON, Mass.

    View source ↗